Featured Research

from universities, journals, and other organizations

JAMA Study Shows New 'biologic' Drug Reduces Psoriasis Symptoms, Improves Quality Of Life

Date:
December 24, 2003
Source:
Loyola University Health System
Summary:
A new "biologic" drug, efalizumab, reduces the thick, red, scaly skin lesions of psoriasis, and improves patient quality of life, according to a study in the Dec. 17 Journal of the American Medical Association.

MAYWOOD, Ill. – A new "biologic" drug, efalizumab, reduces the thick, red, scaly skin lesions of psoriasis, and improves patient quality of life, according to a study in the Dec. 17 Journal of the American Medical Association.

"Biologics are a new approach to treating psoriasis," said lead author Dr. Kenneth Gordon, director of the Loyola Psoriasis Center, Loyola University Health System, Maywood, Ill. "The symptom relief with biologics is achieved without many of the side effects of traditional psoriasis treatment."

Gordon and colleagues conducted a double-blind, placebo-controlled study of efalizumab on 556 adult psoriasis patients at 30 centers in the U.S. and Canada. Patients received weekly injections of the drug or a placebo for three months. Researchers assessed the extent of the psoriasis on the head, upper and lower limbs, and trunk of each patient. In addition, they rated the degree of scaling and thickness.

"Psoriasis is triggered by an immune system response that induces skin cells to grow too quickly," said Gordon, associate professor of medicine, division of dermatology, Loyola University Chicago Stritch School of Medicine, Maywood, Ill. "The skin cells also do not mature normally. As a result, the skin piles up and forms red, scaly, thick plaque lesions.

For the study, patients completed a questionnaire asking how psoriasis affects their daily life, work and their relationships. They also reported symptoms, including pain, itching, bleeding, burning and scaling.

"Biologics are injected, instead of swallowed, and block immune cells that produce the dry, flaky skin," said Gordon, who serves on the National Psoriasis Foundation's medical board. Efalizumab modulates T-cells. Found in the blood supply, T-cells bolster the body's immune response.

The researchers evaluated the effects of efalizumab on health-related quality of life measures from both patient and physician perspective. "Psoriasis can compromise physical, social and emotional well-being," said Gordon.

Results of the study shows that the patients who received the biologic therapy achieve significant improvement vs. placebo.

"The efalizumab treatment reduced the frequency and severity of psoriasis symptoms, particularly in the severity of itching and scaling," said Gordon.

Psoriasis can develop at any age, although it usually shows up in 15- to 35-year-olds. Average age at diagnosis: 28 years. Earlier medicines for psoriasis had side effects, such as liver or kidney toxicity. Psoriasis can be triggered by stress, certain medicines or injury to the skin. Because 33 percent of people with psoriasis have a family history of the disease, it is impossible to know who will get psoriasis.

Affecting five million Americans (average age at diagnosis: 28 years), psoriasis has no cure but effective new treatments are emerging with medications called "biologics."

"No medicine is appropriate for everyone," said Gordon. "Individuals must check with their doctor before pursuing any psoriasis therapy."

Visit the Loyola University Health System Web site http://www.luhs.org for more information. To schedule an appointment with Gordon, call (708) 216-3835.

Gordon has received research finding from Genentech, Inc.


Story Source:

The above story is based on materials provided by Loyola University Health System. Note: Materials may be edited for content and length.


Cite This Page:

Loyola University Health System. "JAMA Study Shows New 'biologic' Drug Reduces Psoriasis Symptoms, Improves Quality Of Life." ScienceDaily. ScienceDaily, 24 December 2003. <www.sciencedaily.com/releases/2003/12/031223070303.htm>.
Loyola University Health System. (2003, December 24). JAMA Study Shows New 'biologic' Drug Reduces Psoriasis Symptoms, Improves Quality Of Life. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2003/12/031223070303.htm
Loyola University Health System. "JAMA Study Shows New 'biologic' Drug Reduces Psoriasis Symptoms, Improves Quality Of Life." ScienceDaily. www.sciencedaily.com/releases/2003/12/031223070303.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins